Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2020
‘Korea should introduce indication-specific drug pricing’
31 August 2020 - “Korea must introduce a system to apply different prices for a drug’s multiple indications, to guarantee ...
Posted by Michael Wonder on 31 Aug 2020
New Zealand Pharmaceutical Schedule - 1 September 2020
1 September 2020 - The September 2020 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Aug 2020
New hope for Australian leukaemia and lymphoma patients with key treatment option listed on PBS
31 August 2020 - A key new cancer treatment has just become more accessible for Australians fighting specific forms of leukaemia ...
Posted by Michael Wonder on 30 Aug 2020
New poll shows wide support for several Trump drug pricing reforms, but not rebate changes
28 August 2020 - Voters in several battleground states overwhelmingly support several of President Trump’s recent proposals to drastically cut ...
Posted by Michael Wonder on 30 Aug 2020
Petition urges PHARMAC to fund Crohn's and colitis medication
29 August 2020 - Thousands of people are backing a petition to improve the lives of hundreds of New Zealanders with ...
Posted by Michael Wonder on 30 Aug 2020
FDA grants priority review of melflufen for patients with triple-class refractory multiple myeloma
29 August 2020 - Oncopeptides today announces that the US FDA has granted priority review for Oncopeptides' new drug application ...
Posted by Michael Wonder on 29 Aug 2020
FDA broadens emergency use authorisation for Veklury (remdesivir) to include all hospitalised patients for treatment of COVID-19
28 August 2020 - Today, as part of its ongoing efforts to fight COVID-19, the U.S. FDA broadened the scope of ...
Posted by Michael Wonder on 29 Aug 2020
Rybelsus is included in the high-cost protection with restriction
28 August 2020 - Rybelsus (semaglutide) is intended for the treatment of adults with type 2 diabetes in adults as the ...
Posted by Michael Wonder on 28 Aug 2020
U.S. FDA approves Cystadrops (0.37% cysteamine ophthalmic solution), a new practical treatment option for the ocular manifestations of cystinosis
25 August 2020 - Recordati Rare Diseases today announced the U.S. FDA has approved Cystadrops (0.37% cysteamine ophthalmic solution). ...
Posted by Michael Wonder on 28 Aug 2020
Kidney cancer charity slams NICE rejection of Keytruda/Inlyta
28 August 2020 - MSD’s Keytruda (pembrolizumab) in combination with Pfizer's Inlyta (axitinib) has been turned down by NICE as ...
Posted by Michael Wonder on 28 Aug 2020
Rocket Pharmaceuticals receives FDA fast track designation for RP-L401 gene therapy for infantile malignant osteopetrosis
27 August 2020 - Rocket’s fifth gene therapy program receives fast track designation. ...
Posted by Michael Wonder on 27 Aug 2020
Trump has launched an all-out attack on the FDA. Will its scientific integrity survive?
27 August 2020 - President Trump has instigated an all-out crusade against the FDA at a critical point in the ...
Posted by Michael Wonder on 27 Aug 2020
This is a heart drug that the world doesn’t need
27 August 2020 - Twenty years ago, perhaps the hottest area of drug research was on a class of compounds called ...
Posted by Michael Wonder on 27 Aug 2020
Drug makers to sue government for limiting choline alfoscerate benefit
27 August 2020 - Manufacturers of choline alfoscerate, a dementia drug, are reportedly preparing to file an administrative lawsuit against ...
Posted by Michael Wonder on 27 Aug 2020
FDA works to evaluate cancer therapies in patients with brain metastases
27 August 2020 - Today, the U.S. FDA issued a draft guidance document, “Evaluating Cancer Drugs in Patients with Central Nervous ...